BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) CEO Talks Key Aspects of Company’s Technology, Personalized Breast Cancer Treatment
BriaCell is on its way to developing a personalized, off-the-shelf immunotherapy for advanced breast cancer patients Because of the market gap and the demand for such treatments, the development and release of the product could be fast tracked BriaCell has obtained excellent results in clinical trials so far as Bria-IMT demonstrates the ability to shrink tumors at multiple sites in patients with advanced breast cancer BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is developing the first personalized, off-the-shelf advanced breast cancer immunotherapy option using its proprietary targeted immunotherapy technology, company president and CEO Dr. Bill Williams said in a recent…